CSI Market
Sign In | Register

Applied Therapeutics Inc (APLT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access APLT Annual Cash Flow →
This cash flow overview for Applied Therapeutics Inc spans from Sep 30 2024 to Sep 30 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-62.15
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.73
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-2.17
Fair Value Adjustment Of Derivatives-
Operating Lease Right Of Use Asset Amortization-
Increase Decrease In Accrued Liabilities And Other Current Liabilities7.35
Operating Lease Right Of Use Asset Amortization Expense0.32
Payment Of Security Deposit And Leasehold Improvements For Long Term Lease-
Increase Decrease In Operating Lease Liability-0.30
Increase Decrease In Financed Insurance Premium-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.29
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-15.46
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-67.38
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.09
Proceeds From Issuance Of Convertible Preferred Stock Net Of Cash Issuance Costs-
Payments Of Stock Issuance Costs Excluding Convertible Preferred Stock-
Proceeds From Issuance Of Redeemable Convertible Preferred Stock Net Of Cash Issuance Costs-
Payments Of Stock Issuance Costs Initial Public Offering-
Proceeds From Issuance Initial Public Offering Net-
Directors And Officers Insurance Premium Short Term Note-
Marketable Securities Unrealized Gain Loss-
Conversion Of Preferred Stock To Equity-
Stock Issuance Costs In Accrued Expenses-
Stock Issuance Costs In Accounts Payable-
Payments Of Deferred Offering Costs-
Proceeds From Issuance Of Common Stock Net-
Proceeds From Financed Insurance Premium-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.08
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-67.38
Total Cash Flow-67.45
4 historic quarters locked

Sign in to unlock the full Applied Therapeutics Inc cash flow history.

Sign In Create Free Account

About Applied Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20250930)
  • Filed with the SEC: November 13, 2025
  • Source: aplt-20250930.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-25-278818

Figures are derived from filed reports and may be restated. Historical data is subject to revision.